Treatment of Advanced Endometrial Carcinoma with Tamoxifen

Abstract

To the Editor: The work of Kelley and Baker, first reported in 1960,¹ established the efficacy and safety of progestational agents in the treatment of advanced endometrial carcinoma and has been the basis for hormonal therapy of the disease. Clearly, however, many patients with endometrial cancer do not respond to high-dose progestins. Other patients respond to progestins but subsequently relapse. No alternative form of hormonal therapy is yet available.It has been shown² that cytosol from nonmalignant and malignant endometrial tissue contains measurable quantities of both progesterone and estrogen receptors. Also, the regulation of levels of both receptors is similar . . .